K. Hoekman

发表

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

J. Schellens, H. Rosing, J. Beijnen, 2002, Anti-cancer drugs.

Clinical and Preclinical Modulation of Chemotherapy-Induced Toxicity in Patients with Cancer

J. Vermorken, W. J. Vijgh, K. Hoekman, 2012, Drugs.

Doxorubicin gradients in human breast cancer.

J. Lankelma, P. Diest, H. Pinedo, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets.

H. Verheul, H. Pinedo, H. Broxterman, 2000, Blood.

Automated serum peptide profiling using novel magnetic C18 beads off‐line coupled to MALDI‐TOF‐MS

G. Giaccone, A. Smit, F. Kruyt, 2007, Proteomics. Clinical applications.

Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.

J. Berkhof, V. V. van Hinsbergh, M. Levi, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Renal cell carcinoma and interleukin-2: a review.

J. Baars, J. Wagstaff, C. Hack, 1995, European journal of cancer.

Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate

C. Löwik, S. Papapoulos, K. Hoekman, 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Regulation of parathyroid hormonelike protein production in cultured normal and malignant keratinocytes.

R. Offringa, M. Ponec, G. Hendy, 1992, The Journal of investigative dermatology.

VEGF and Endostatin Levels in Wound Fluid and Plasma after Breast Surgery

M. Cuesta, S. Meijer, K. Hoekman, 2004, Angiogenesis.

Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer.

P. V. van Diest, S. Linn, H. Verheul, 1997, American journal of clinical pathology.

Analysis of Coagulation Cascade and Endothelial Cell Activation During Inhibition of Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Pathway in Cancer Patients

V. V. van Hinsbergh, M. Levi, P. Kostense, 2002, Arteriosclerosis, thrombosis, and vascular biology.

The hemostatic system in angiogenesis.

V. V. van Hinsbergh, P. Koolwijk, K. Hoekman, 2005, EXS.

Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.

E. Smit, H. Verheul, H. Pinedo, 2000, The oncologist.

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.

G. Giaccone, C. Punt, E. Voest, 2010, European journal of cancer.

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.

H. van Tinteren, H. Tinteren, J. Wagstaff, 1993, British Journal of Cancer.

A doxorubicin-CNGRC-peptide conjugate with prodrug properties.

J. Lankelma, H. Pinedo, H. Broxterman, 2002, Biochemical pharmacology.

Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.

H. Verheul, H. Pinedo, R. Hanemaaijer, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour

S. Meijer, H. Pinedo, R. Hanemaaijer, 2004, Journal of Clinical Pathology.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) decreases left ventricular function. An echocardiographic study in cancer patients.

O. Kamp, W. Lagrand, A. Groeneveld, 2001, Cytokine.

Advanced Glycation End Products in Human Cancer Tissues: Detection of Nε‐(Carboxymethyl)lysine and Argpyrimidine

C. Schalkwijk, H. Niessen, K. Hoekman, 2005, Annals of the New York Academy of Sciences.

VEGFR 2 expressing circulating ( progenitor ) cell populations in volunteers and cancer patients

C. Gundy, G. Schuurhuis, H. Broxterman, 2018 .

Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity

G. Peters, M. Fukushima, F. Kruyt, 2003, British Journal of Cancer.

Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumor-induced hypoglycemia.

J. van Doorn, K. Hoekman, C. Hoogerbrugge, 2002, Clinical chemistry.

Hypoglycaemia associated with the production of insulin‐like growth factor II and insulin‐like growth factor binding protein 6 by a haemangiopericytoma

J. Maassen, H. Pinedo, J. van Doorn, 1999, Clinical endocrinology.

Direct activation of caspases by RGD-peptides may increase drug sensitivity of tumour cells.

H. Broxterman, K. Hoekman, 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Arginine supplementation in the prevention and treatment of osteoporosis.

K. Hoekman, J. Visser, 1994, Medical hypotheses.

Tumour-induced hypoglycaemia: a case report.

O. Hoekstra, J. Wagstaff, H. Pinedo, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract 4956: CD34bright/CD133negcandidate circulating endothelial progenitor cells (ccEPCs) are a potential biomarker during treatment with sunitinib or bevacizumab

E. Smit, G. Schuurhuis, A. Veldt, 2008 .

Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis.

S. Papapoulos, K. Hoekman, O. Bijvoet, 1985, The Journal of clinical endocrinology and metabolism.

Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis.

L. Aarden, C. Löwik, G. van der Pluijm, 1989, Biochemical and biophysical research communications.

Dose-Finding Study of the Multitargeted Tyrosine Kinase Inhibitor SU6668 in Patients with Advanced Malignancies

G. Giaccone, A. Kok, C. Schalkwijk, 2005, Clinical Cancer Research.

Dose-Finding Study of theMultitargeted Tyrosine Kinase Inhibitor SU 6668 in Patients with AdvancedMalignancies

G. Giaccone, A. Kok, C. Schalkwijk, 2005 .

Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine.

C. Schalkwijk, Jeroen W J van Heijst, H. Niessen, 2005, Annals of the New York Academy of Sciences.

Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors.

G. Giaccone, C. Punt, E. Voest, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of the production of a parathyroid hormone-like protein in human squamous carcinoma cell lines by interaction with fibroblasts.

M. Ponec, C. Löwik, K. Hoekman, 1990, Cancer Research.

Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer.

J. Wagstaff, H. Pinedo, J. Vermorken, 1991, Journal of the National Cancer Institute.

Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.

G. Giaccone, G. Schuurhuis, E. van der Wall, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.

R. Verheijen, C. Burger, J. Vermorken, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.

W. M. Smit, H. Hollema, F. Erdkamp, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer.

L. Thomsen, C. Hack, A. Ogilvie, 1996, Journal of immunology.

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

J. Baselga, I. Chirivella, J. Tabernero, 2010, Clinical Cancer Research.

Effects of major liver resection, with or without recombinant bactericidal/permeability‐increasing protein (rBPI21), on the angiogenic profile of patients with metastatic colorectal carcinoma

M. Cuesta, S. Meijer, C. Meijer, 2003, Journal of surgical oncology.

Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells.

J. Verheijen, C. Löwik, S. Papapoulos, 1991, Bone and mineral.

Clostridium septicumMyonecrosis and Ovarian Cancer: A Case Report and Review of Literature

C. Burger, H. M. Prinssen, K. Hoekman, 1999 .

Can Pha Act

I. Chirivella, J. Tabernero, P. Elvin, 2010 .

Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly

N. Aaronson, M. Muller, C. Leemans, 2006, Cancer.

The role of nitric oxide in bacterial meningitis in children.

W. Hop, A. J. van der Heijden, R. de Groot, 1996, The Journal of infectious diseases.

adhesion and activation of platelets stimulated endothelial cells promote - Vascular endothelial growth factor

H. Verheul, H. Pinedo, H. Broxterman, 2013 .

5-Fluorouracil/leucovorin-induced inhibition of thymidylate synthase in normal tissues of mouse and man

G. Peters, S. Meijer, C. L. van der Wilt, 1997, Journal of Cancer Research and Clinical Oncology.

Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.

H. van Cruijsen, K. Hoekman, A. V. D. van der Veldt, 2009, Frontiers in bioscience.

Thymidine Phosphorylase in Angiogenesis and Drug Resistance

G. Peters, M. Fukushima, S. Ackland, 2002 .

Thymidine phosphorylase in angiogenesis and drug resistance. Homology with platelet-derived endothelial cell growth factor.

G. Peters, M. Fukushima, S. Ackland, 2000, Advances in experimental medicine and biology.

Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.

V. V. van Hinsbergh, C. Löwik, G. van der Pluijm, 2007, European journal of cancer.

Enhanced systemic nitric oxide production in inflammatory bowel disease

A. Peña, K. Hoekman, J. Visser, 1993, The Lancet.

A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile.

S. Linn, H. Verheul, H. Pinedo, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy and Toxicity of the Angiogenesis Inhibitor SU 5416 As a Single Agent in Patients with Advanced Renal Cell Carcinoma , Melanoma , and Soft Tissue Sarcoma 1

F. Cavalli, A. Harris, J. Baselga, 2003 .

Platelet: transporter of vascular endothelial growth factor.

H. Verheul, C. Folman, H. Pinedo, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival

G. Giaccone, J. Haanen, T. D. de Gruijl, 2008, Clinical Cancer Research.

Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences.

J. Lankelma, H. Broxterman, K. Hoekman, 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer.

G. Giaccone, S. Linn, H. Pinedo, 1996, British Journal of Cancer.

Systemic and Peritoneal Angiogenic Response After Laparoscopic or Conventional Colon Resection in Cancer Patients: A Prospective, Randomized Trial

M. Cuesta, C. Sietses, S. Meijer, 2003, Diseases of the colon and rectum.

Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.

H. Verheul, H. Pinedo, P. Van Der Valk, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Acute leukemia following therapy for teratoma.

J. Mcvie, W. W. ten Bokkel Huinink, K. Hoekman, 1984, European journal of cancer & clinical oncology.

Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.

G. Peters, P. Diest, G. J. Peters, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of platelet derived endothelial cell growth factor / thymidine phosphorylase in health and diseaseArticle

G. Peters, H. Pinedo, K. Hoekman, 2006 .

Neurotoxic Complications of Chemotherapy in Patients with Cancer

Jan J. Heimans, J. Heimans, T. Postma, 2012, Drugs.

The effect of fluoropyrimidines with or without thymidine phosphorylase inhibitor on the expression of thymidine phosphorylase.

G. Peters, M. Fukushima, H. Pinedo, 2004, European journal of pharmacology.

Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells.

G. Peters, M. Fukushima, H. Pinedo, 2003, Biochemical and biophysical research communications.

Expression of drug resistance proteins in breast cancer, in relation to chemotherapy

G. Giaccone, S. Linn, H. Pinedo, 1997, International journal of cancer.

Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor

G. Giaccone, T. D. de Gruijl, H. van Cruijsen, 2007, Clinical & developmental immunology.

Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts

P. V. van Diest, H. Pinedo, H. Broxterman, 2004, Clinical Cancer Research.

MMP‐9 Activity in Urine from Patients with Various Tumors, as Measured by a Novel MMP Activity Assay Using Modified Urokinase as a Substrate

Cornelis F. M. Sier, J. Verheijen, R. Hanemaaijer, 1999, Annals of the New York Academy of Sciences.

The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients

Martijn R. Meijerink, G. Giaccone, R. Manoliu, 2007, European Radiology.

W. M. Smit, H. Hollema, P. Willemse, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Proteomics of the TRAP-induced platelet releasate.

H. Verheul, S. Piersma, H. Broxterman, 2009, Journal of proteomics.

SU6668, a multitargeted angiogenesis inhibitor.

K. Hoekman, 2001, Cancer journal.

The EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy

G. Giaccone, K. Hoekman, H. Cruijsen, 2008 .

Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies

G. Giaccone, H. van Cruijsen, K. Hoekman, 2005, International journal of cancer.

Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib

D. Kuik, J. Haanen, H. Verheul, 2009, Angiogenesis.

Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.

F. Barkhof, A. Veldt, F. Barkhof, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.

Sylvia, G. Giaccone, E. Wall, 1999, The oncologist.

Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients.

G. Giaccone, J. Wagstaff, H. Pinedo, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Reversible thyroid dysfunction during treatment with GM-CSF

H. Drexhage, J. Wagstaff, H. Pinedo, 1991, The Lancet.

The effect of tissue type plasminogen activator (tPA) on osteoclastic resorption in embryonic mouse long bone explants: a possible role for the growth factor domain of tPA.

J. Verheijen, C. Löwik, S. Papapoulos, 1992, Bone and mineral.

Angiogenesis: a potential target for therapy of soft tissue sarcomas.

H. Pinedo, K. Hoekman, 2004, Cancer treatment and research.

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.

G. Giaccone, H. Pinedo, H. Broxterman, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.

G. Giaccone, S. Linn, J. Wagstaff, 1998, British Journal of Cancer.

Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition.

G. Giaccone, T. D. de Gruijl, H. van Cruijsen, 2011, Immunotherapy.

The role of 1,25‐dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone‐related protein

S. Papapoulos, K. Hoekman, Y. I. Tjandra, 1991, Cancer.

Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.

J. Wagstaff, H. Pinedo, J. Vermorken, 1996, British Journal of Cancer.

Potentiation of 5-fluorouracil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent.

S. Meijer, C. L. van der Wilt, H. Pinedo, 1993, Advances in experimental medicine and biology.

The effects of surgery, with or without rhGM-CSF, on the angiogenic profile of patients treated for colorectal carcinoma.

M. Cuesta, S. Meijer, P. V. van Leeuwen, 2004, Cytokine.

Argpyrimidine-modified Heat shock protein 27 in human non-small cell lung cancer: a possible mechanism for evasion of apoptosis.

C. Schalkwijk, V. V. van Hinsbergh, R. Musters, 2006, Cancer letters.

Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

F. Cavalli, A. Harris, J. Baselga, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

J. Wanders, J. Beijnen, J. Smyth, 2003, European journal of cancer.

VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients

C. Gundy, V. V. van Hinsbergh, G. Schuurhuis, 2007, Thrombosis and Haemostasis.

(PROGENITOR) CELL POPULATIONS IN VOLUNTEERS AND CANCER PATIENTS

C. Gundy, G. Schuurhuis, H. Broxterman, 2010 .

Nitric Oxide Synthesis in Meningococcal Meningitis

K. Hoekman, R. Scholten, J. Visser, 1994, Annals of Internal Medicine.

Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers

J. Baselga, J. Tabernero, H. Hurwitz, 2007 .

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.

J. Schellens, E. Voest, J. Drevs, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical evaluation of AZD2171 in combination with gefitinib, in patients with advanced tumors

G. Giaccone, M. Koehler, E. Voest, 2005 .

[Coagulation disorders in cancer patients: possible opportunity for therapy].

H. Verheul, H. Pinedo, K. Hoekman, 2000, Nederlands tijdschrift voor geneeskunde.

Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: A randomized phase II study of cediranib

J. Schellens, E. Voest, C. Unger, 2008 .

705 POSTER Evaluation of thyroid function in an open-label Phase I study of AZD2171 with gefitinib

G. Giaccone, C. Punt, E. Voest, 2007 .

[The hematopoietic growth factor GM-CSF in chemotherapy for advanced breast carcinoma].

J. Wagstaff, H. Pinedo, J. Vermorken, 1991, Nederlands tijdschrift voor geneeskunde.

Highly sensitive and specific detection of P-glycoprotein function for haematological and solid tumour cells using a novel nucleic acid stain.

K. Hoekman, H. M. Pinedo, M. Poot, 1997, British Journal of Cancer.

Role of Platelet Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase in Fluoropyrimidine Sensitivity and Potential Role of Deoxyribose‐1‐Phosphate

G. Peters, M. Fukushima, H. Pinedo, 2004, Nucleosides, nucleotides & nucleic acids.

Phase II study of paclitaxel (taxol, gemcitabine, and cisplatin for patients with advanced ovarian cancer)

H. Pinedo, R. Verheyen, K. Hoekman, 2001 .

Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer

J. Heimans, T. Postma, C. Verstappen, 2003, Journal of Neuro-Oncology.

Clinical Cancer esearch cer Therapy : Clinical se I Safety , Pharmacokinetics , and Inhibition of Src R ivity Study of Saracatinib in Patients with Solid Tumors

I. Chirivella, J. Tabernero, P. Elvin, 2010 .

Treatment of haemangiopericytoma-associated hypoglycaemia with embolisation.

H. Pinedo, P. Nanayakkara, K. Hoekman, 2002, European journal of internal medicine.

Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.

E. Smit, H. Verheul, H. Pinedo, 2000, The oncologist.

Expression of drug resistance proteins in breast cancer, in relation to chemotherapy

G. Giaccone, S. Linn, H. Pinedo, 1997, International journal of cancer.